SNCA and Parkinson disease: Although it may be concluded that quantification of alpha-synuclein deposition in pilomotor muscles is a valid biomarker for PD, this technique is limited by its invasive nature and by the uncertainty of whether the alpha-synuclein staining detected in the nerves is, indeed, the cause of the observed symptomatic functional deficits.